For healthcare professionals. This information does not replace clinical judgement in the individual case; the current summary of product characteristics and the guidelines cited are authoritative.
Medically reviewed: Dr. med. univ. Daniel Pehböck, DESA, 01.11.2026
Landiolol (β1-selective beta blocker, ultra-short-acting (half-life approx. 4 min)) – indications: SVT, atrial fibrillation/flutter with rapid ventricular rate (including perioperative use). Weight-based dosing in mg and ml in the app, with sources.
Indications
- SVT, atrial fibrillation/flutter with rapid ventricular rate (including perioperative use)
Complete in the app
Weight-based doses in mg and ml, preparations, contraindications and notes – in the app, also offline.
Sources and guidelines
- Summaries of product characteristics of authorised products – product and section for each dose in the app.